TScan Therapeutics (TCRX) Short-term Investments (2023 - 2025)

TScan Therapeutics (TCRX) has reported Short-term Investments for 3 consecutive years, with $14.9 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Short-term Investments fell 89.17% year-over-year to $14.9 million; the TTM figure through Sep 2025 stood at $14.9 million (down 89.17% YoY), while the FY2024 annual figure was $111.4 million, up 89.86% from the prior year.
• Short-term Investments declined to $14.9 million in Q3 2025 per TCRX's latest filing, from $48.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $138.0 million in Q3 2024 and bottomed at $14.9 million in Q3 2025.
• Historically, Short-term Investments has averaged $67.5 million across 3 years, with a median of $58.7 million in 2023.
• On a YoY basis, Short-term Investments climbed as much as 338.17% in 2025 and fell as far as 89.17% in 2025.
• TScan Therapeutics' Short-term Investments stood at $58.7 million in 2023, then jumped by 89.86% to $111.4 million in 2024, then tumbled by 86.59% to $14.9 million in 2025.
• Business Quant data shows TCRX's Short-term Investments at $14.9 million in Q3 2025, $48.7 million in Q2 2025, and $97.6 million in Q1 2025.